Influenza vaccine in the elderly and chronic obstructive pulmonary disease

被引：1
作者：
Lupatkin H. [1 ]
机构：
[1] Department of Medicine, Division of Infectious Diseases, New York University School of Medicine, New York, NY 10016
来源：
Current Infectious Disease Reports | 2005年 / 7卷 / 3期
关键词：
Chronic Obstructive Pulmonary Disease; Influenza; Influenza Virus; Influenza Vaccine; Influenza Vaccination;
D O I：
10.1007/s11908-005-0035-8
中图分类号：
学科分类号：
摘要：
Influenza viruses are RNA viruses that are a major determinant of morbility and mortality caused by respiratory disease. Influenza is highly contagious and has caused epidemics and pandemics for centuries. Most influenza infections are self-limited, but lower respiratory tract and cardiac complications can result in increases in hospitalizations and deaths. The recommended composition of influenza vaccine is updated annually in order to provide a vaccine that is antigenically well matched with the new influenza virus strains that are expected to cause epidemics. Influenza vaccination significantly reduces mortality; however, approximately one third of elderly Americans are not immunized annually. The nation's goal is to increase the influenza vaccination rate among the elderly to 90%. Vaccination is the most effective measure for reducing the impact of influenza and is a cost-effective preventive health intervention for the elderly and individuals with chronic obstructive pulmonary disease. Copyright © 2005 by Current Science Inc.
引用
收藏
页码：200 / 203
页数：3
相关论文
共 27 条
  • [1] Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Morb. Mortal Wkly. Rep., 53, pp. 1-44, (2004)
  • [2] Thompson W.W., Shay D.K., Weintraub E., Et al., Mortality associated with influenza and respiratory syncytial virus in the United States, JAMA, 289, pp. 179-186, (2003)
  • [3] Healthy People 2010: Understanding and Improving Health, (2000)
  • [4] Edwards K.M., Dupont W.D., Westrich M.K., Et al., A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease, J. Infect. Dis., 169, pp. 68-76, (1994)
  • [5] Govaert T.M., Thijis C.T., Masurel N., Et al., The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial, JAMA, 272, pp. 1661-1665, (1994)
  • [6] Vu T., Farish S., Jenkins M., Kelly H., A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community, Vaccine, 20, pp. 1831-1836, (2002)
  • [7] Gross P.A., Hermogenes A.W., Sacks H.S., Et al., The efficacy of influenza vaccine in elderly persons: A meta-analysis and review of the literature, Ann. Intern. Med., 123, pp. 518-527, (1995)
  • [8] Hak E., Nordin J., Wei E., Et al., Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations, Clin. Infect. Dis., 35, pp. 370-377, (2002)
  • [9] Wang C.S., Wang S.T., Lai C.T., Et al., Reducing major cause-specific hospitalization rates and shortening hospital stays after influenza vaccination, Clin. Infect. Dis., 39, pp. 1604-1610, (2004)
  • [10] Collins S.D., Excess mortality from causes other than influenza and pneumonia during influenza epidemics, Public Health Report (Wash.), 47, pp. 2159-2179, (1932)
123